Transaction · 0001193125-26-008023

Guyer William

Guyer William, CDO, reported an open-market or private sale at CORCEPT THERAPEUTICS INC involving 20000.000000 shares for an estimated $703656.00. Reported holdings after the transaction were 1235.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SCDO
CORTCORCEPT THERAPEUTICS INC
Filing timeJan 09
Trade dateJan 06, 2026
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$37.50
Pre-filing
1mo ago +129.6%1w ago +87.2%1d ago -6.8%
Returns since
7d -7.4%30d +8.9%90d +12.7%180d +147.8%1y +211.8%

CORT price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
CORT since 2026-01-09Filed 238 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001193125-26-008023
Common Stock
Transaction date
Jan 06, 2026
Filed Jan 09, 2026, 01:35 AM · 3d delay
Shares
20.0k sh
$3.51k per share
Estimated value
-$70.3M
Computed from shares × price
Holdings after
1.23k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Direct Ownership Large Holdings Reduction 10b5-1 Detected
-4score
Filing-only score

-4

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Development Officer

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction.

  2. F2

    Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $34.96 to $35.50 per share. Information on the exact number of shares sold at each sa…

  3. F3

    Fully exercisable.

Original filing · 0001193125-26-008023
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

CORT